• Home | Global Data CRO
  • Our Company
    • About Us
    • Executive Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Global Leaders
    • Working with MMS
    • Certifications
  • Services
    • Regulatory Affairs
      • Regulatory Affairs Services
      • Regulatory Strategy Consulting
      • Regulatory Affairs Management
      • Regulatory Operations
    • Data Management and Biostatistics
    • Regulatory and Medical Writing
    • Transparency Services
      • Transparency and Disclosure Services
      • REGISTRATION AND RESULTS DISCLOSURES
      • DATA AND DOCUMENT ANONYMIZATION
      • LAY SUMMARIES
    • Quality and Compliance services
    • Drug Safety and Pharmacovigilance
    • Rare Disease
    • Quality Control Services
    • Project Advisory Services
    • Data Science
  • Technology
    • Datacise
    • Automatiqc
    • PVantage
    • Technology Implementation
    • SmartStart Document Templates
  • Functional Services (FSP)
  • Webinars
  • News and Media
  • MMS Blog
  • Careers
    • MMS Careers
    • Opportunities
    • MMS Experience
    • MMS Culture
    • Global Benefits
    • FAQ
  • Learning
  • Contact Us
MMS Holdings
11 traits to transition from a bench scientist to a medical writer

11 traits to transition from a bench scientist to a medical writer

by curtis@digitalliance.com | Jun 21, 2018 | Blog

Many Ph.D. graduate students are led to believe that there are only two routes to take after graduation: Research projects in academia or industry.  On the contrary, one thing that many do not see is that they have obtained a set of unique, invaluable skills that can...
Society needs to change to embrace open discussions on suicide

Society needs to change to embrace open discussions on suicide

by curtis@digitalliance.com | Jun 14, 2018 | Blog

One person dies from suicide every 40 seconds across the globe according to the World Health Organization (WHO), and the world is currently mourning two, with the unfortunate circumstances surrounding Kate Spade and Anthony Bourdain. However, suicidality is not always...
Building a robust clinical data science process

Building a robust clinical data science process

by curtis@digitalliance.com | Jun 7, 2018 | Blog

During PhUSE US Connect 2018 – the clinical data science conference – in Raleigh, North Carolina, MMS data science experts presented a paper and corresponding poster, titled Big Data Paradox: Development of a Unique and Repeatable Analytical Process while Implementing...
Ask the Expert: The Future of Drug Development

Ask the Expert: The Future of Drug Development

by curtis@digitalliance.com | May 31, 2018 | Blog

The size of the global pharmaceutical market will reach $1.12 trillion by the year 2022, according to Pharmaceutical Commerce. Yet, many questions linger about what the future of drug development will look like, including technology that will impact the industry and...
Why Should GDPR Matter to all Clinical Research Firms?

Why Should GDPR Matter to all Clinical Research Firms?

by curtis@digitalliance.com | May 24, 2018 | Blog

Since the beginning of 2018, there has been a growing interest from pharmaceutical and biotech firms in the United States regarding the basic tenets of the European Union’s (EU) new General Data Protections Regulation (GDPR) law. With more than 50 percent of all...
Page 1 of 512345»

Recent Posts

  • MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise
  • New FDA Policies and Procedures for Products Submitted Under Accelerated Pathways : Understanding CDER MAPP 5015.13
  • 10 Things to Consider When Discussing and Planning a Decentralized Clinical Trial (DCT)
  • SENDing Successful Nonclinical Submissions through Validation, Review, and Beyond
  • Orphan Drug Designations in the EU: Recent Rare Disease Treatment Updates

Tags

biostatistics Careers clinical research clinical study reports clinical trial disclosure clinical trials clinical trial transparency Compliance conference COVID-19 CRO data management data privacy data science decentralized clinical trials diversity and inclusion drug development eCOA & ePro EMA FDA Functional Service Provider (FSP) GXP auditing Health Analytics Collective innovation Lay summaries leadership medical writing MMS Academy NDA submission News Orphan Drug Designation Applications PDUFA VII pharmacovigilance PhUSE plain language summary Policy 0070 Praxis bioresearch quality and compliance quality control rare disease real world data regulatory affairs regulatory operations statistical programming transparency